Literature DB >> 30250212

Biallelic mutations in FDXR cause neurodegeneration associated with inflammation.

Jesse Slone1, Yanyan Peng1, Adam Chamberlin2, Belinda Harris3, Julie Kaylor4, Marie T McDonald5, Monica Lemmon5, Mays Antonine El-Dairi6, Dmitry Tchapyjnikov5, Laura A Gonzalez-Krellwitz7, Elizabeth A Sellars4, Allyn McConkie-Rosell5, Laura G Reinholdt3, Taosheng Huang8,9.   

Abstract

Mitochondrial dysfunction lies behind many neurodegenerative disorders, owing largely to the intense energy requirements of most neurons. Such mitochondrial dysfunction may work through a variety of mechanisms, from direct disruption of the electron transport chain to abnormal mitochondrial biogenesis. Recently, we have identified biallelic mutations in the mitochondrial flavoprotein "ferredoxin reductase" (FDXR) gene as a novel cause of mitochondriopathy, peripheral neuropathy, and optic atrophy. In this report, we expand upon those results by describing two new cases of disease-causing FDXR variants in patients with variable severity of phenotypes, including evidence of an inflammatory response in brain autopsy. To investigate the underlying pathogenesis, we examined neurodegeneration in a mouse model. We found that Fdxr mutant mouse brain tissues share pathological changes similar to those seen in patient autopsy material, including increased astrocytes. Furthermore, we show that these abnormalities are associated with increased levels of markers for both neurodegeneration and gliosis, with the latter implying inflammation as a major factor in the pathology of Fdxr mutations. These data provide further insight into the pathogenic mechanism of FDXR-mediated central neuropathy, and suggest an avenue for mechanistic studies that will ultimately inform treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30250212      PMCID: PMC6451867          DOI: 10.1038/s10038-018-0515-y

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  34 in total

1.  A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies.

Authors:  Y Goto; I Nonaka; S Horai
Journal:  Nature       Date:  1990-12-13       Impact factor: 49.962

2.  Functional reconstitution of mitochondrial Fe/S cluster synthesis on Isu1 reveals the involvement of ferredoxin.

Authors:  Holger Webert; Sven-Andreas Freibert; Angelo Gallo; Torsten Heidenreich; Uwe Linne; Stefan Amlacher; Ed Hurt; Ulrich Mühlenhoff; Lucia Banci; Roland Lill
Journal:  Nat Commun       Date:  2014-10-31       Impact factor: 14.919

Review 3.  Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis.

Authors:  I Hanukoglu
Journal:  J Steroid Biochem Mol Biol       Date:  1992-12       Impact factor: 4.292

4.  Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis.

Authors:  Yanbo Shi; Manik Ghosh; Gennadiy Kovtunovych; Daniel R Crooks; Tracey A Rouault
Journal:  Biochim Biophys Acta       Date:  2011-11-10

5.  Mitochondrial cytochrome P-450scc. Mechanism of electron transport by adrenodoxin.

Authors:  I Hanukoglu; C R Jefcoate
Journal:  J Biol Chem       Date:  1980-04-10       Impact factor: 5.157

Review 6.  A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine.

Authors:  Douglas C Wallace
Journal:  Annu Rev Genet       Date:  2005       Impact factor: 16.830

7.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Authors:  David Devos; Caroline Moreau; Jean Christophe Devedjian; Jérome Kluza; Maud Petrault; Charlotte Laloux; Aurélie Jonneaux; Gilles Ryckewaert; Guillaume Garçon; Nathalie Rouaix; Alain Duhamel; Patrice Jissendi; Kathy Dujardin; Florent Auger; Laura Ravasi; Lucie Hopes; Guillaume Grolez; Wance Firdaus; Bernard Sablonnière; Isabelle Strubi-Vuillaume; Noel Zahr; Alain Destée; Jean-Christophe Corvol; Dominik Pöltl; Marcel Leist; Christian Rose; Luc Defebvre; Philippe Marchetti; Z Ioav Cabantchik; Régis Bordet
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

8.  Loss of SLC25A46 causes neurodegeneration by affecting mitochondrial dynamics and energy production in mice.

Authors:  Zhuo Li; Yanyan Peng; Robert B Hufnagel; Yueh-Chiang Hu; Chuntao Zhao; Luis F Queme; Zaza Khuchua; Ashley M Driver; Fei Dong; Q Richard Lu; Diana M Lindquist; Michael P Jankowski; Rolf W Stottmann; Winston W Y Kao; Taosheng Huang
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

9.  Human adrenodoxin reductase: two mRNAs encoded by a single gene on chromosome 17cen----q25 are expressed in steroidogenic tissues.

Authors:  S B Solish; J Picado-Leonard; Y Morel; R W Kuhn; T K Mohandas; I Hanukoglu; W L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

Review 10.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

View more
  7 in total

1.  FDXR regulates TP73 tumor suppressor via IRP2 to modulate aging and tumor suppression.

Authors:  Jin Zhang; Xiangmudong Kong; Yanhong Zhang; Wenqiang Sun; Jian Wang; Mingyi Chen; Xinbin Chen
Journal:  J Pathol       Date:  2020-05-18       Impact factor: 7.996

Review 2.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

3.  Expanding the FDXR-Associated Disease Phenotype: Retinal Dystrophy Is a Recurrent Ocular Feature.

Authors:  Neringa Jurkute; Priya D Shanmugarajah; Marios Hadjivassiliou; Jenny Higgs; Miodrag Vojcic; Iain Horrocks; Yann Nadjar; Valerie Touitou; Guy Lenaers; Roy Poh; James Acheson; Anthony G Robson; F Lucy Raymond; Mary M Reilly; Patrick Yu-Wai-Man; Anthony T Moore; Andrew R Webster; Gavin Arno
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-05-03       Impact factor: 4.799

Review 4.  Mitochondrial DNA Variants and Common Diseases: A Mathematical Model for the Diversity of Age-Related mtDNA Mutations.

Authors:  Huanzheng Li; Jesse Slone; Lin Fei; Taosheng Huang
Journal:  Cells       Date:  2019-06-18       Impact factor: 6.600

5.  Mechanisms of MEHP Inhibitory Action and Analysis of Potential Replacement Plasticizers on Leydig Cell Steroidogenesis.

Authors:  Annick N Enangue Njembele; Jacques J Tremblay
Journal:  Int J Mol Sci       Date:  2021-10-24       Impact factor: 5.923

6.  Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.

Authors:  Yi He; Salvador Alejo; Prabhakar Pitta Venkata; Jessica D Johnson; Ilanna Loeffel; Uday P Pratap; Yi Zou; Zhao Lai; Rajeshwar R Tekmal; Edward R Kost; Gangadhara R Sareddy
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

7.  Diagnostic testing laboratories are valuable partners for disease gene discovery: 5-year experience with GeneMatcher.

Authors:  Meghan C Towne; Mari Rossi; Bess Wayburn; Jennifer M Huang; Kelly Radtke; Wendy Alcaraz; Kelly D Farwell Hagman; Deepali N Shinde
Journal:  Hum Mutat       Date:  2022-03-02       Impact factor: 4.700

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.